Phentolamine Eye Drops Reverse Pharmacologically Induced Mydriasis in a Randomized Phase 2b Trial
| Autor: | Eliot Lazar, Arin T Amin, Jay S. Pepose, Shane R Kannarr, Mina Sooch, Reda M Jaber, Konstantinos Charizanis, Paul M. Karpecki, Gerald D Horn, Marguerite B. McDonald, Alan R. Meyer, Shane Foster, Stephen Montaquila, Charles B. Slonim, Jonah E Yousif, Seth A Klapman |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Mydriatics genetic structures Adolescent Administration Ophthalmic Phenylephrine Tropicamide Young Adult Phentolamine Blurred vision Double-Blind Method Pupil Disorders Ophthalmology medicine Pupillary response Mydriasis Humans Adrenergic alpha-Antagonists Cross-Over Studies medicine.diagnostic_test business.industry Accommodation Ocular Cycloplegia Pupil eye diseases Eye examination sense organs medicine.symptom Ophthalmic Solutions business Optometry medicine.drug |
| Zdroj: | Optometry and vision science : official publication of the American Academy of Optometry. 98(3) |
| ISSN: | 1538-9235 |
| Popis: | SIGNIFICANCE After a dilated eye examination, many patients experience symptoms of prolonged light sensitivity, blurred vision, and cycloplegia associated with pharmacological mydriasis. Phentolamine mesylate ophthalmic solution (PMOS) may expedite the reversal of mydriasis in patients, potentially facilitating return to functional vision and reducing barriers to obtaining dilated eye examinations. PURPOSE The protracted reversal time after pharmacologically induced pupil dilation impairs vision. We tested the hypothesis that PMOS rapidly reduces pupil diameter in this acute indication. METHODS In this double-masked placebo-controlled, randomized, two-arm crossover phase 2b trial, we evaluated the effects of one drop of 1% PMOS applied bilaterally in subjects who had their pupils dilated by one of two common mydriatic agents: 2.5% phenylephrine or 1% tropicamide. End points included change in pupil diameter, percent of subjects returning to baseline pupil diameter, and accommodative function at multiple time points. RESULTS Thirty-one subjects completed the study (15 dilated with phenylephrine and 16 with tropicamide). Change in pupil diameter from baseline at 2 hours after maximal dilation with 1% PMOS was -1.69 mm and was significantly greater in magnitude compared with placebo for every time point beyond 30 minutes (P < .05). At 2 hours, a greater percentage of study eyes given 1% PMOS returned to baseline pupil diameter compared with placebo (29 vs. 13%, P = .03), which was this also seen at 4 hours (P < .001). More subjects treated with PMOS in the tropicamide subgroup had at least one eye returning to baseline accommodative amplitude at 2 hours (63 vs. 38%, P = .01). There were no severe adverse events, with only mild to moderate conjunctival hyperemia that resolved in most patients by 6 hours. CONCLUSIONS Phentolamine mesylate ophthalmic solution at 1% reversed medically induced pupil dilation more rapidly than placebo treatment regardless of which mydriatic was used (adrenergic agonists and cholinergic blockers) with a tolerable safety profile. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|